Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 first-in-human single and multiple ascending dose study of R2R01 in healthy volunteers
NL-OMON51081Phase 1Completed
- Sponsor
- River 2 Renal Corp
- Start
- Apr 2021
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of R2R01 in kidney failure (8 cohorts), sponsored by River 2 Renal Corp. Primary endpoint: Safety and tolerability. Started Apr 2021; status: completed.
02
Drugs
R2R01
03
Conditions
kidney failure
Beyond the preview
Go deeper on NL-OMON51081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51081.